Endocannabinoids have both anti-inflammatory and neuroprotective properties against harmful stimuli. We previously demonstrated that the endocannabinoid 2-arachidonoylglycerol (2-AG) protects hippocampal neurons by limiting the inflammatory response via a CB1 receptor-dependent MAPK/NF-kB signalling pathway. The purpose of the present study was to determine whether PPARg, an important nuclear receptor, mediates 2-AG-induced inhibition of NF-kB phosphorylation and COX-2 expression, and COX-2-enhanced miniature spontaneous excitatory postsynaptic currents (mEPSCs).
Introduction
Endocannabinoids (eCBs) are endogenous signalling mediators involved in a variety of physiological, pharmacological and pathological processes (Freund et al., 2003; Kano et al., 2009; Marrs et al., 2010; Pertwee et al., 2010) . The eCB system consists of eCBs, cannabinoid receptors (CB1 and CB2), enzymes synthesizing eCBs and metabolizing eCBs and cannabinoid transporters. Emerging evidence now suggests that eCBs possess anti-inflammatory and neuroprotective properties against harmful insults (Marsicano et al., 2003; Walter and Stella, 2004; Panikashvili et al., 2001; , 2006 Eljaschewitsch et al., 2006; Mackie, 2006; Centonze et al., 2007; Zhang and Chen, 2008; Chen et al., 2011) . Neuroinflammation is the immune system's response to infection and injury in the CNS and has been implicated in the pathogeneses and neuropathology of many prevalent neurological and neurodegenerative diseases, such as multiple sclerosis, Alzheimer's and Parkinson's diseases (Chen, 2010) . However, there are currently no effective medications to prevent chronic inflammation and alleviate or treat chronic inflammation-induced brain disorders. As eCBs have the ability to restrict inflammation, they may have the potential to prevent neuropathology and treat neuroinflammation-induced brain disorders. While eCB modulation of both GABAergic and glutamatergic synaptic transmission and plasticity via a CB1 receptordependent mechanism has been extensively investigated (Alger, 2002; Freund et al., 2003; Piomelli, 2003; Chevaleyre et al., 2006; Mackie, 2006; Kano et al., 2009) , the mechanisms underlying the ability of eCB to limit neuroinflammation and provide neuronal protection have not been elucidated (Sarne and Mechoulam, 2005; Van der Stelt and Di Marzo, 2005; Fowler et al., 2010) .
PPARs are members of the nuclear receptors/transcription factors super-family. Three different PPAR genes (PPARa, PPARd -also called PPARb and PPARg) have been identified. These nuclear receptors regulate expression of the genes involved in metabolism, cell differentiation and inflammation (Daynes and Jones, 2002; Kozak et al., 2002; LunaMedina et al., 2005; Drew et al., 2006; Bensinger and Tontonoz, 2008; Bright et al., 2008; Necela et al., 2008) . Growing evidence suggests that PPARs are likely a target for eCBs (Lenman and Fowler, 2007; O'Sullivan, 2007; Sun et al., 2007; O'Sullivan and Kendall, 2010; Pertwee et al., 2010; Pistis and Melis, 2010) . However, little information is available as to whether PPARs are involved in this inhibitory effect of eCBs on neuroinflammation. 2-Arachidonoyl glycerol (2-AG), the most abundant eCB and a full agonist for CB1 and CB2 receptors (Sugiura et al., 2006; Kano et al., 2009) , has been shown to be an important endogenous signalling mediator protecting neurons from pro-inflammatory, excitotoxic stimuli and other harmful insults (Gopez et al., 2005; Panikashvili et al., 2001; , 2006 Melis et al., 2006; Kreutz et al., 2007) . Rockwell et al. (2006) demonstrated that 2-AGinduced suppression of IL-2 in Jurkat T cells is mediated by activation of PPARg through a CB1/2 receptor-independent mechanism. We demonstrated previously that direct application of 2-AG or elevation of endogenous 2-AG by inhibiting its hydrolysis protects hippocampal neurons from the effects of pro-inflammatory IL-1b and LPS, excitotoxic glutamate and kanaic acid and b-amyloid stimuli by limiting COX-2 expression via a CB 1 receptor-dependent NF-kB signalling pathway Chen et al., 2011) . In this report, we show that 2-AG-induced suppression of NF-kB phosphorylation, COX-2 expression and COX-2 elevationenhanced excitatory synaptic transmission in hippocampal neurons in culture in response to pro-inflammatory insults is mediated by the CB1 receptor-dependent expression of PPARg.
Methods

Cell culture
Primary hippocampal neurons from mouse pups (P0 to P1) were cultured as described previously (Sang et al., 2005; 2007 , 2010 Zhang and Chen, 2008; Chen et al., 2011) , according to the guidelines approved by the Institutional Animal Care and Use Committee of the Louisiana State University Health Sciences Center in New Orleans. Briefly, hippocampi were dissected out under a microscope and triturated in serum-free culture medium after the meninges had been removed. Tissue was incubated in oxygenated trypsin for 10 min at 37°C and then mechanically triturated. Cells were spun down and resuspended in Neurobasal/B27 medium (Invitrogen Corp., Carlsbad, CA, USA) supplemented with 0.5 mM L-glutamine, penicillin/streptomycin and 25 mM glutamate. Cells (1 ¥ 10 6 ) were loaded into poly-D-lysine-coated six-well plates for Western blot analysis and 35 mm culture dishes for electrophysiological recordings. Medium was changed every 3 days with the same medium without glutamate until use. The percentage of astroglial cells in the culture was~5% at 10 days in vitro (DIV), as estimated by staining with a neuronal marker NeuN, astrocytic marker GFAP and microglial marker OX-42 in conjunction with the 4′,6-diamidino-2-phenylindole staining as described previously (Sang et al., 2005; Zhang and Chen, 2008) . Cultures were used between 10 and 21 DIV.
Electrophysiological recordings
Miniature spontaneous excitatory postsynaptic currents (mEPSCs) were recorded in hippocampal neurons in culture under voltage clamp using an Axopatch-200B amplifier (Molecular Devices, Palo Alto, CA) as described previously (Sang et al., 2005; 2006 , 2007 , 2010 Zhang and Chen, 2008) . Recording pipettes (4-5 MW) were pulled from borosilicate glass with a micropipette puller (Sutter Instrument, Novato, CA). The internal pipette solution contained (in mM) 115.0 Cs gluconate, 15.0 CsCl, 4.0 NaCl, 10.0 HEPES, 0.5 EGTA, 4.0 Mg2ATP and 0.5 Na2GTP (pH 7.25 with CsOH). The membrane potential was held at -70 mV. The external solution contained (in mM): 130.0 NaCl, 2.5 KCl, 1.0 MgCl2, 10.0 HEPES, 1.25 NaH2PO4, 2.0 CaCl2 and 25.0 glucose (pH 7.4 with NaOH). To isolate mEPSCs, tetrodotoxin (TTX, 0.5 to 1 mM), a voltage-gated Na + channel blocker and bicuculline (10 mM), a GABAA receptor blocker, were included in the external solution. All experiments were performed at room temperature (22-24°C). The frequency, amplitude and kinetics of mEPSCs were analysed using the MiniAnalysis program (Synaptosoft, Fort Lee, NJ).
Immunoblot
Hippocampal neurons in cultures were extracted and immediately homogenized in a one-to-one volume of modified BJP H Du et al.
radioimmunoprecipitation assay lysis buffer consisting of a number of protease inhibitors. Supernatants were fractionated on 10% SDS-PAGE gels (Bio-Rad Lab, Hercules, CA, USA) and transferred onto PVDF membranes (Bio-Rad). The membrane was incubated with anti-COX-2 polyclonal antibodies (dilution of 1:1000; Cayman Chemical, Ann Arbor, MI), anti-NFkB-p65 and phospho-NF-kB antibodies (1:1000; Cell Signaling, Danvers, MA) and anti-PPARg (1:1000; Abcam, Cambridge,MA) at 4°C overnight. The blot was washed and incubated with a secondary antibody (goat anti-rabbit, 1:10 000; Vector Laboratories, Burlingame, CA) at room temperature for 1 h. Proteins were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences, UK). The densities of specific bands were quantified by densitometry using FUJI-FILM Multi Gauge software (version 3.0) (Fujifilm USA Inc., Valhalla, NY, USA). Band densities were normalized to the total amount of protein loaded in each well as determined by mouse anti-b-actin (1:4000; Sigma, St. Louis, MO) as described previously Sang et al., 2005; 2010) .
Chemicals and drugs
2-AG, AEA, URB602, JZL184, 15-deoxy-D 12,14 -prostaglandin J2 (15d-PGJ2), GW9662 and rosiglitazone were purchased from Cayman Chemical. T0070907 was purchased from Tocris Bioscience (Ellisville, MO, USA). These chemicals were dissolved in DMSO to make stock solutions at concentrations of 20 to 50 mM, distributed in small vials and then diluted with the external solution or culture medium to the desired concentrations just before experiments. Rimonabant (provided by Chemical Synthesis and Drug Supply Program, the National Institute of Mental Health) was dissolved in DMSO to make up stock solutions at concentrations of 50 to 100 mM. All other drugs and chemicals were obtained from Sigma, unless stated otherwise. To rule out potentially nonspecific effects of the solvents, the same amount of ethanol or DMSO was included in the control external solution and culture medium. Nomenclature of cannabinoid receptors follows Alexander et al. (2009) .
Data analysis
Data are presented as mean Ϯ SEM. Unless stated otherwise, ANOVA with Fisher's PLSD test or Student-Newman-Keuls test was used for statistical comparison when appropriate. The Kolmogorov-Smirnov test was used for comparisons of mEPSCs distribution. Differences were considered significant when P < 0.05.
Results
Inhibition of COX-2 and NF-kB phosphorylation by 2-AG is mediated by PPARg
To determine whether 2-AG-inudced anti-inflammatory effects involve PPARs, we targeted PPARg since it represses the expression of inflammatory genes in response to proinflammatory stimuli (Bensinger and Tontonoz, 2008) . We used phosphorylation of NF-kB-p65 and expression of COX-2 as biomarkers for neuroinflammation in cultured hippocampal neurons as described previously .
As shown in Figure 1A ,B, phosphorylation of NF-kB-p65 and expression of COX-2 were significantly elevated in hippocampal neurons in culture treated with IL-1b (10 ng·mL -1 ) or LPS (1 mg·mL -1 ), commonly used pro-inflammatory stimuli. This elevation was inhibited or attenuated by exogenous application of 2-AG (3 mM), consistent with our previous observations . However, the suppressive effect of 2-AG on NF-kB-p65 phosphorylation and COX-2 expression induced by IL-1b or LPS was blocked by GW9662 (5 mM), a selective PPARg antagonist. This suggests that the 2-AGproduced suppression of IL-1b-and LPS-induced NF-kB-p65 phosphorylation and COX-2 expression is mediated by PPARg. This was further confirmed by the results showing that IL-1b or LPS down-regulated the expression of PPARg, and this downregulation was prevented or restored by 2-AG ( Figure 1C ,D).
PPARg is involved in 2-AG-induced suppression of COX-2-enhanced excitatory synaptic transmission
An elevation of COX-2 expression by pro-inflammatory IL-1b or LPS enhances mEPSCs (Sang et al., 2005; Zhang and Chen, 2008) . We thus treated cultures with IL-1b or LPS for 16 and 24 h, respectively, and recorded mEPSCs in hippocampal neurons in the absence and presence of 2-AG. As expected, IL-1b or LPS, which elevates COX-2 expression, significantly augmented the frequency but not the amplitude of mEPSCs ( Figure 2 ). This enhancement was suppressed in the presence of 2-AG (1 mM). However, application of GW9662 reversed this 2-AG-induced suppression, suggesting a role for PPARg in the 2-AG-induced suppression of COX-2-enhanced mEPSCs. To further ascertain the effect of PPARg inhibition on 2-AGinduced suppression of mEPSCs in IL-1b-or LPS-treated cultures, we used another selective PPARg antagonist, T0070907 (T007) (Lee et al., 2002) . Similar to GW9662, T007 (1 mM) also blocked the effect of 2-AG ( Figure S1 ). We also measured the kinetics of mEPSCs in IL-1b-or LPS-treated neurons in the absence and presence of 2-AG or GW9662. There were no significant differences in the rise or decay time constants between the vehicle controls and the treated neurons (data not shown).
Endogenous 2-AG-induced suppression of neuroinflammation is mediated by PPARg
To raise the levels of endogenous 2-AG, we used two selective MAGL inhibitors, URB 602 and JZL184. Since JZL184 displays higher selectivity and potency than URB602 for MAGL over FAAH (Hohmann et al., 2005; Long et al., 2009a,b) , we used URB 602 at 10 mM or JZL184 at 1 mM. As seen in Figure 3A -D, administration of URB602 or JZL184 significantly reduced IL-1b-or LPS-induced phosphorylation of NF-kB-p65 and expression of COX-2. URB602-and JZL184-induced suppression of IL-1b-or LPS-induced NF-kB-p65 phosphorylation and COX-2 expression was blocked by GW9662. To determine whether an elevation of endogenous 2-AG is also capable of restoring the IL-1b-or LPS-reduced expression of PPARg, we detected the expression of PPARg in the absence and presence of URB602 or JZL184. As shown in Figure 3E -H, URB602 (10 mM) or JZL184 (1 mM) restored the IL-1b-or LPSinduced down-regulation of PPARg. From these results, it appears that both exogenous and endogenous 2-AG-induced inhibition of COX-2 expression and NF-kB phosphorylation are mediated by PPARg.
PPARg is involved in endogenous 2-AG-induced suppression of COX-2-enhanced excitatory synaptic transmission
If the exogenous application of 2-AG is capable of suppressing the COX-2-enhanced mEPSCs, then elevating the level of endogenous 2-AG by inhibiting its hydrolysis, as described above, should also be able to inhibit the enhanced frequency of mEPSCs in IL-1b-or LPS-treated cultures. Moreover, if PPARg mediates this endogenous 2-AG-induced suppression of NF-kB phosphorylation and COX-2 expression, then blockade of PPARg should be able to reverse the endogenous 2-AG-induced suppression of COX-2-enhanced mEPSCs. As seen in Figures 4 and 5 , treating the culture with URB602 or JZL184 significantly reduced IL-1b-or LPS-induced
Figure 1
Exogenous application of 2-AG suppresses NF-kB phosphorylation and COX-2 expression and elevates PPARg expression in response to pro-inflammatory IL-1b and LPS insults. Hippocampal neurons in culture were treated with IL-1b (10 ng·mL -1 ) for 6 h or LPS (1 mg·mL -1 ) for 16 h in the absence and presence of 2-AG or GW9662 (5 mM). The different time points used for the treatments of IL-1b and LPS were based on our previous studies where we identified that IL-1b-or LPS-induced COX-2 expression and NF-kB phosphorylation reached the peaks at these time points . 2-AG or GW9662 was added 30 min before IL-1b or LPS application. (A1-A2) Immunoblot analysis of 2-AG suppression of LPS-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (B1-B2) Immunoblot analysis of 2-AG suppression of IL-1b-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (C1-C2) 2-AG restores LPS-induced down-regulation of PPARg (n = 3). (D1-D2) 2-AG restores IL-1b-induced down-regulation of PPARg (n = 3). **P < 0.01, compared with the vehicle control; ##P < 0.01 compared with IL-1b or LPS; §P < 0.05, § §P < 0.01 compared with IL-1b+2-AG or LPS+2-AG. enhancement of mEPSCs frequency, suggesting that an elevation of endogenous 2-AG also is capable of preventing the increase in excitatory synaptic transmission induced by COX-2. The URB602-or JZL184-produced suppression was blocked by GW9662. This suggests that, similar to the effects of exogenously applied 2-AG, the elevation of endogenous 2-AG produced by inhibiting MAGL is sufficient to reduce the release of excitatory neurotransmitter glutamates induced by COX-2 and PPARg mediates this inhibitory effect of endogenous 2-AG on excitatory synaptic transmission.
PPARg agonists suppress phosphorylation of NF-kB, expression of COX-2 and enhancement of mEPSCs induced by IL-1b and LPS
To determine whether PPARg agonists or activators mimic the actions of 2-AG in resolving IL-1b-or LPS-induced NF-kB-p65 phosphorylation, COX-2 expression and enhanced mEPSCs, we used 15-deoxy-D 12,14 -prostaglandin J2 (15d-PGJ2) and rosiglitazone (Ros), both PPARg agonists (Park et al., 2003) . As seen in Figure 6 , administration of 15d-PGJ2 (2 mM) or Ros (1 mM) significantly reduced IL-1b-or LPS-induced phosphorylation of NF-kB-p65 and expression of COX-2; these effects of 15d-PGJ2 and Ros were blocked by GW9662. Similarly, 15d-PGJ2 and Ros also suppressed IL-1b-or LPS-induced enhancement of mEPSCs, and again this suppression was blocked by antagonism of PPARg (Figures 7 and 8 ).
CB 1 receptor mediates 2-AG-produced restoration of reduced PPARg expression by LPS
To determine whether 2-AG-induced increase in PPAR expression is dependent on CB1 receptors, we conducted another set of experiments where the culture was treated with rimonabant (RIM), a selective CB1 receptor antagonist, in the presence of LPS and 2-AG, URB602 or JZL184. As shown in Figure 9A -C, LPS significantly decreased the expression of PPARg, and this decrease was restored by 2-AG (3 mM), URB602 (10 mM) or JZL184 (1 mM). However, the action of 2-AG, URB602 or JZJ184 on PPARg expression was blocked by RIM (1 mM), suggesting a CB1 receptor-mediated effect. To further confirm that restoration of the LPS-suppressed PPARg expression by direct application of 2-AG or enhancement of endogenous 2-AG is mediated via a CB1 receptor, we treated cultured hippocampal neurons from mice deficient in the CB1 receptor with LPS in the presence of 2-AG, URB602 or JZl184. As shown in Figure 9D , 2-AG, URB602 or JZl184 failed to restore the LPS-induced suppression of PPARg, confirming that the action of 2-AG on PPARg expression is CB1 receptordependent. To determine whether endogenous 2-AGproduced suppression of LPS-or IL-1b-induced enhancement of mEPSCs is also mediated via a CB1 receptor, we recorded mEPSCs in culture treated with RIM in the presence of LPS or IL-1b and URB602. As illustrated in Figure S2 , URB602-induced suppression of the increase in mEPSCs induced by LPS-or IL-1b was blocked by RIM (1 mM). These results suggest that 2-AG-induced increase in PPARg expression is mediated primarily via the CB1 receptor.
We need to mention here that 2-AG or URB602 alone did not alter the basal expression of COX-2 or the basal activity of mEPSCs. This is consistent with previously described observations . In addition, we demonstrated that treating the culture with JZL184, rosiglitazone, 15d-PGJ 2 or GW alone did not alter the basal activity of mEPSCs (data not shown). In particular, we provide evidence that JZL184, Ros, 15d-PGJ2 or GW9662 alone did not significantly alter the basal expression of COX-2 ( Figure S3 ). This suggests that 2-AG probably functions as an important signalling mediator maintaining the homeostasis of brain function.
Discussion and conclusion
In the present study, we provide evidence that exogenous application of 2-AG or the elevation of endogenous 2-AG, produced by inhibiting its hydrolysis with selective MAGL inhibitors URB602 and JZl184, is capable of suppressing NF-kB-p65 phosphorylation and COX-2 expression. This expands upon our previous work where we discovered that 2-AG protects neurons against harmful insults by limiting the inflammatory response Chen et al., 2011) . In particular, we demonstrate here that the 2-AGproduced suppression NF-kB-p65 phosphorylation, COX-2 expression and mEPSC enhancement by pro-inflammatory IL-1b-or LPS is mediated via PPARg. This suggests PPARg is a target for 2-AG in protecting neurons against proinflammatory insults. Since the anti-neuroinflammatory effects and restoration of the LPS-reduced PPARg expression by exogenous and endogenous 2-AG are largely blocked by pharmacological or genetic inhibition of the CB1 receptor, the actions of 2-AG were not through direct interaction with nuclear PPARg. More likely, they are mediated primarily by CB1 receptor-dependent changes in PPARg expression.
Arachidonoyl ethanolamide (AEA or anandamide) and 2-AG are the two most studied eCBs. However, despite their similar chemical structure, 2-AG and AEA display distinct profiles in their synthesis, metabolism, cannabinoid receptor binding affinity and synaptic modulation (Freund et al., 2003; Sugiura et al., 2006; Kano et al., 2009) . In particular, AEA and 2-AG exhibit differences in their ability to limit neuroinflammation and protect neurons from harmful insults. For instance, 2-AG has been shown to protect neurons from brain ischaemia, traumatic brain injury and pro-inflammatory stimuli (Panikashvili et al., 2001; , 2006 Melis et al., 2006; Kreutz et al., 2007; Zhang and Chen, 2008 ). However, AEA shows a paradoxical phenomenon in its neuroprotective effects against inflammatory and excitotoxic stimuli and even induces neurotoxicity per se Movsesyan et al., 2004; Sarne and Mechoulam, 2005; Van der Stelt and Di Marzo, 2005; Fowler et al., 2010) . This implies that 2-AG is probably an endogenously intrinsic signalling mediator protecting neurons against harmful insults and maintaining tissue homeostasis . Since the exogenous application or endogenous elevation of 2-AG suppressed the pro-inflammatory IL-1b-or LPS-induced phosphorylation of NF-kB-p65 and expression of COX-2 (two key markers in inflammation), strengthening the 2-AG signalling pathway by inhibition of MAGL will be beneficial in resolving neuroinflammation, which is the root of many neurological disorders and neurodegenerative diseases (Chen, 2010) . MAGL is the enzyme that hydrolyzes 85% of 2-AG in the brain (Blankman et al., 2007) . Thus, inhibiting MAGL with selective MAGL inhibitors will raise the levels of endogenous 2-AG (Hohmann et al., 2005; Comelli et al., 2007; King et al., 2007; Long et al., 2009a; 2009b; Pan et al., 2009) . As such, this may lead to potential interventions for preventing, alleviating and treating brain disorders associated with neuroinflammation.
Although PPARg was originally shown to regulate lipid metabolism and adipocyte differentiation, there is accumulating evidence indicating that PPARg possesses antiinflammatory and neuroprotective properties, induced by regulating the transcription of genes involved in inflammation (Jiang et al., 1998; Ricote et al., 1998; Daynes and Jones, 2002; Luna-Medina et al., 2005; Drew et al., 2006; Bensinger and Tontonoz, 2008; Bright et al., 2008; Necela et al., 2008; Racke and Drew, 2008) . PPARg regulates gene transcription by binding to conserved DNA sequences termed peroxisome proliferator response elements (PPRE) as heterodimers with retinoic X receptor (Bensinger and Tontonoz, 2008) . Increasing evidence suggests that eCBs are probably PPARg activators (O'Sullivan, 2007; Sun et al., 2007; O'Sullivan and Kendall, 2010; Pertwee et al., 2010; Pistis and Melis, 2010) . It has been shown that 2-AG suppression of the expression of IL-2, an autocrine/paracrine T-cell growth factor, is mediated via a CB 1/2 receptor-independent activation of PPARg (Rockwell et al., 2006) , suggesting that 2-AG may be able to directly activate nuclear PPARg by crossing both the plasma and nuclear membranes (O'Sullivan, 2007; Sun et al., 2007; O'Sullivan and Kendall, 2010; Pistis and Melis, 2010) . However, 2-AG may also be able to activate PPARg and restore neuroinflammation-induced down-regulation of PPARg expression through a CB1 receptor-dependent pathway. In the present study, we observed that exogenous and endogenous 2-AG-produced suppression of NF-kB-p65 phosphorylation and COX-2 expression in response to proinflammatory IL-1b or LPS are blocked by antagonism of PPARg with a selective PPARg inhibitor. Moreover, 2-AG prevented the IL-1b-or LPS-induced down-regulation of PPARg. It has been shown previously that COX-2 participates in synaptic transmission and plasticity via PGE2, which facilitates the synaptic release of the excitatory neurotransmitter glutamate (Chen et al., 2002; Chen and Bazan, 2005; Sang et al., 2005; Slanina and Schweitzer, 2005; Akaneya and Tsumoto, 2006; . We demonstrated that the frequency of the mEPSCs in cultured hippocampal neurons is significantly elevated by an increase in COX-2 expression, and this enhancement is suppressed by 2-AG . However, 2-AG-produced suppression of COX-2-enhance mEPSCs was blocked or attenuated by antagonism of PPARg. Our results provide convincing evidence that PPARg probably mediates 2-AG-produced inhibition of COX-2 expression and NF-kB phosphorylation.
Based on our previous and present results, PPARg may not be directly targeted by 2-AG because inhibition of the CB 1 receptor eliminates or decreases the effects 2-AG on neuroinflammation and neuroprotection. For instance, we demonstrated previously that 2-AG-produced neuroprotection and suppression of COX-2 expression in response to proinflammatory and other harmful insults are mediated via CB1 receptor-dependent inhibition of MAPK/NF-kB phosphorylation Chen et al., 2011) . In addition, inhibition of the CB1 receptor blocked URB602-produced suppression of IL-1b-or LPS-enhanced mEPSCs ( Figure S2 ). In particular, pharmacological and genetic inhibition of the CB1 receptor significantly attenuated restorative effect of 2-AG on IL-1b-or LPS-induced down-regulation of PPARg (Figure 9 ). If the actions of 2-AG on NF-kB phosphorylation and COX-2 expression are through crossing both the plasma and nuclear membranes to directly activate PPARg, then inhibition of the CB1 receptor, which is expressed on the surface plasma membrane, should fail to inhibit 2-AG-induced expression of PPARg that regulates the expression of genes involved inflammation. In addition, antagonism of the CB1 receptor should fail to block 2-AG suppression of COX-2-induced increase in mEPSCs. Apparently, this is not the case. This indicates that the signalling mechanisms mediating 2-AG-induced activation/expression of PPARg in our study are different from those implicated by Rockwell et al., (2006) . The exact mechanism for this discrepancy between the two studies is still not clear, but it is probably due to the different preparations used.
A recent study shows that the suppression of IL-2 in T cells produced by AEA or 2-AG is COX-2-dependent (Rockwell et al., 2008) . 2-AG and AEA are substrates for COX-2 and can be oxidatively metabolized by COX-2 to prostaglandin glycerol esters or ethanolamides (Kozak et al., 2004; . However, it is not clear which COX-2 metabolites mediate the 2-AG-or AEA-induced IL-2 suppression. We demonstrated previously that the effects of COX-2 metabolites of 2-AG on synaptic transmission and neurodegeneration are opposite to that of their precursor 2-AG (Sang et al., , 2007 Zhang and Chen, 2008) . For instance, acute application of PGE2-G, a major COX-2 metabolite of 2-AG, enhances excitatory synaptic transmission, while 2-AG inhibits it in cultured hippocampal neurons. Moreover, treatment of neurons in culture Figure 2 2-AG inhibits COX-2 elevation-induced enhancement of mEPSCs. Hippocampal neurons in culture were treated with IL-1b (10 ng·mL -1 ) for 16 h or LPS (2 mg·mL -1 ) for 24 h in the absence and presence of 2-AG (1 mM) or GW9662 (5 mM). The different time points used for the treatment of IL-1b and LPS were based on our previous studies where we identified that IL-1b or LPS significantly enhanced synaptic activity at these time points (Sang et al., 2005; Zhang and Chen, 2008) 
Figure 3
Endogenous 2-AG suppresses NF-kB phosphorylation and COX-2 expression and prevents down-regulation of PPARg expression induced by IL-1b and LPS. Hippocampal neurons in culture treated with IL-1b (10 ng·mL -1 ) or LPS (1 mg·mL -1 ) were the same as described in Figure 1 . Selective MAGL inhibitors URB602 (URB, 10 mM) and JZL184 (1 mM) were added to the culture 30 min before IL-1b or LPS application in order to elevate endogenous 2-AG. (A1-A2) Immunoblot analysis of URB suppression of LPS-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (B1-B2) Immunoblot analysis of URB suppression of IL-1b-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (C1-C2) Immunoblot analysis of JZL184 suppression of LPS-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (D1-D2) Immunoblot analysis of JZL184 suppression of IL-1b-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (E1-H2). Elevation of endogenous 2-AG by inhibiting MAGL with URB602 or JZL184 restores LPS-or IL-1b-induced down-regulation of PPARg (n = 3 per group). **P < 0.01, compared with the vehicle control; ##P < 0.01 compared with IL-1b or LPS; §P < 0.05, § §P < 0.01 compared with IL-1b + URB or JZL184, LPS+URB or JZL184.
with PGE2-G induces neurodegeneration and apoptosis and increases NF-kB phosphorylation, while 2-AG protects neurons against neurodegeneration and apoptosis and inhibits NF-kB phosphorylation. Therefore, in our study it is unlikely that 2-AG-produced suppression of COX-2 expression and NF-kB-p65 phosphorylation and increase of PPARg expression are mediated through COX-2 metabolites of 2-AG.
It has been proposed that there is a reciprocally negative feedback loop between NF-kB and PPARg, suggesting that there is cross-talk between these two transcription factors (Bensinger and Tontonoz, 2008; Necela et al., 2008) . We speculate that under physiological conditions, inflammatory genes are tonically repressed by co-repressor complexes. However, exposure to pro-inflammatory stimuli such as IL-1b or LPS activates astroglial toll-like receptor 4 (TLR4) or IL-1 receptors, which elevate phosphorylation of MAPK and NF-kB. Increased expression and activity of NF-kB not only suppresses PPARg expression and activity but also directly triggers inflammatory gene transcription. The CB1 receptor is expressed both in hippocampal neurons and astroglial cells (Sinha et al., 1998; Waksman et al., 1999; Stella, 2004; Eljaschewitsch et al., 2006; Zhang and Chen, 2008) . Thus, 2-AG binds to Gi-coupled CB1 receptors and/or CB2 receptors. Activation of CB1/2 receptors suppresses phosphorylation of NF-kB through ERK/p38MAPK and increases the expression of PPARg, which represses inflammatory gene transcription (Bensinger and Tontonoz, 2008; Necela et al., 2008) . Nevertheless, the possibility that 2-AG could cross the plasma and nuclear membranes to directly induce PPARg activation and expression, leading to repression 
Figure 6
PPARg agonists inhibit phosphorylation of NF-kB and expression of COX-2 induced by IL-1b-and LPS. Hippocampal neurons in culture-treated with IL-1b (10 ng·mL -1 ) or LPS (1 mg·mL -1 ) were the same as described in Figure 1 . PPARg agonists 15d-PGJ2 (2 mM) or rosiglitazone (Ros, 1 mM) were added to the culture 30 min before IL-1b or LPS. (A1-A2) Immunoblot analysis of 15d-PGJ2 suppression of LPS-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (B1--B) Immunoblot analysis of 15d-PGJ2 inhibition of IL-1b-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (C1-C2) Immunoblot analysis of Ros suppression of LPS-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW9662 (n = 3). (D1-D2) Immunoblot analysis of Ros suppression of IL-1b-induced NF-kB-p65 phosphorylation and COX-2 expression in the absence and presence of GW (n = 3). **P < 0.01, compared with the vehicle control; ##P < 0.01 compared with IL-1b or LPS; §P < 0.05, § §P < 0.01 compared with IL-1b+15d-PGJ2 or Ros, LPS+15d-PGJ2 or Ros.
of NF-kB and inflammatory gene transcription, cannot be excluded. It is likely that 2-AG-initiated signalling events prevent or inhibit inflammatory gene transcription, resulting in resolution of inflammation and neuroprotection.
In this study, we provide evidence for the first time that PPARg mediates exogenous and endogenous 2-AG-produced suppression of pro-inflammatory IL-1b-or LPS-induced NF-kB-p65 phosphorylation and COX-2 expression, the two key inflammatory markers. We also provide evidence that PPARg mediates exogenous and endogenous 2-AG-produced inhibition of enhanced mEPSCs resulting from COX-2 elevation in hippocampal neurons in culture. 2-AG-induced PPARg
Figure 7
PPARg agonist 15d-PGJ2 reduces COX-2 elevation-induced enhancement of mEPSCs. Hippocampal neurons in culture-treated with IL-1b or LPS were the same as described in Figure expression appears to be dependent on the CB1 receptor and interplay between NF-kB-p65 and PPARg, indicating that this would be a previously unrevealed signalling pathway mediating 2-AG-produced anti-inflammatory and neuroprotective effects. However, it is still not clear how the interaction or cross-talk between NF-kB and PPARg occurs when 2-AG activates the CB1 receptor. More work is needed to elucidate this intriguing signalling pathway. Resolution of neuroinflammation is believed to be an efficacious therapeutic approach for prevention and treatment of neurodegenerative diseases such as Alzheimer's disease (Walker and Lue, 2007; Chen, 2010; Glass et al., 2010) . Therefore, the results obtained in the present study suggest that endogenous 2-AG plays an important role in regulation of innate and adaptive immune systems in maintaining tissue homeostasis, and that approaches strengthening endogenous 2-AG signalling by inhibiting its hydrolysis or facilitating its synthesis will be potentially efficacious therapeutic interventions for preventing, relieving and treating chronic neuroinflammationinduced brain disorders.
Figure 9
Exogenous and endogenous 2-AG prevents IL-1b-and LPS-induced decrease in PPARg expression via a CB1 receptor-dependent mechanism. Hippocampal neurons in culture were treated with LPS (1 mg·mL -1 ) for 6 h. 2-AG (A1-A2), URB602 (B1-B2), JZL184 (C1-C2) or rimonabant (RIM, 1 mM) were administered 30 min before LPS. Expression of PPARg was detected using the immunoblot analysis. **P < 0.01 compared with the vehicle control; #P < 0.05, ##P < 0.01 compared with LPS; §P < 0.05 compared with LPS+2-AG, + URB or +JZL184 (n = 3 per group). Hippocampal neurons in culture from mice deficient in the CB1 receptor were treated with LPS (1 mg·mL -1 ) for 6 h in the absence and presence of 2-AG, URB602 or JZL184 (D1-D2). **P < 0.01 compared with the vehicle control. There are no statistically significant differences between LPS and LPS+2-AG, LPS+URB602 or LPS+JZl184 (n = 3 per group).
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Figure S1 Inhibition of PPARg blocks 2-AG-produced suppression of COX-2 elevation-induced enhancement of mEPSCs. T007: T0070907 (1 mM). Figure S2 Inhibition of the CB1 receptor eliminates URB602 suppression of COX-2 elevation-induced enhancement of mEPSCs. RIM: rimonabant (1 mM). Figure S3 JZL184, rosiglitazone (Ros), 15d-PGJ2, or GW9662 alone do not significantly alter basal expression of COX-2 in cultured hippocampal neurons. The treatment of JZL184, Ros, 15d-PGJ2 and GW9662 was the same as that described in other figures. COX-2 expression was detected using Western blot analysis.
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